Akeega – which combines the active ingredients in J&J's PARP inhibitor Zejula (niraparib) and androgen blocker Zytiga ...

Global Akeega sales will reach $676 million by 2030, while Talzenna and saruparib reach $618 million and $628 million ...

Pfizer has pledged a whopping $1 billion upfront ... with drugs like CDK4/6 inhibitor Ibrance (palbociclib), PARP inhibitor Talzenna (talazoparib), hormonal therapy Aromasin (exemestane) and ...

The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC) ...

a million-square-foot warehouse proposed on the former Pfizer Pigments site at Wood Avenue and Hackett Avenue. Most of the site rests in Wilson, with some land in the city of Easton and a ...